Company Intervacc AB

Stocks

IVACC

SE0009607252

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 13:00:00 2026-10-28 EDT			5-day change	1st Jan Change
0.7850 ^SEK	+1.42%		-7.10%	-15.04%

08-20	Intervacc AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	Calendar Thursday, August 20	FW

Business description: Intervacc AB

Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Companyâ€™s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.

Number of employees: 16

Sales by Activity: Intervacc AB

Fiscal Period: December	2021 (SEK)	2022 (SEK)	2023 (SEK)	2024 (SEK)	2025 (SEK)
Pharmaceuticals	8.92M	12.35M	8.03M	11.79M	20.09M

See all business segments

Executive Committee: Intervacc AB

Manager	Title	Age	Since
Carl-Johan Dalsgaard CEO	Chief Executive Officer	70	2026-02-04
Jan Persson DFI	Director of Finance/CFO	-	2020-02-05
Andrew Waller CTO	Chief Tech/Sci/R&D Officer	-	2020-06-10
Patrik Hellberg CIO	Chief Investment Officer	-	-
Anna-Carin Lagerlöf SAM	Sales & Marketing	-	2025-10-31

See INTERVACC AB governance

Composition of the Board of Directors: Intervacc AB

Director	Title	Age	Since
Emil Billbäck CHM	Chairman	56	2026-05-12
Carl Erik Mathias Uhlén BRD	Director/Board Member	72	2023-12-31
Björn Ingemar Odlander BRD	Director/Board Member	68	2024-12-31
Sven Håkan Björklund CHM	Chairman	70	2022-12-31
Lisen Bratt Fredricson BRD	Director/Board Member	-	2022-12-31
Erling Lennart Johansson BRD	Director/Board Member	71	2022-12-31
Camilla Ramfelt McCarthy BRD	Director/Board Member	-	2022-12-31

Composition of the Board of Directors

Shareholders: Intervacc AB

Name	Stocks	%	Valuation
HealthCap IX Investments AB 25.89 %	88,235,294	25.89 %	9 M kr
M Lundberg 2.44 %	8,316,666	2.44 %	845 140 kr
H Bjorklund 2.439 %	8,312,158	2.439 %	844 681 kr
Fjärde AP-fonden (Investment Management) 2.369 %	8,074,000	2.369 %	820 480 kr
Coeli Asset Management AB 1.903 %	6,486,282	1.903 %	659 136 kr

List of INTERVACC AB shareholders

Company details: Intervacc AB

Intervacc AB

Vastertorpsvagen 135 B

129 44, Stockholm

+46 8 12 01 06 00

http://www.intervacc.com

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTERVACC AB	+1.42%	-7.10%	-21.42%	-86.11%	26.55M
WUXI APPTEC CO., LTD.	+0.65%	-3.56%	+33.53%	+60.50%	63.48B
ARGENX SE	+1.76%	+1.27%	+11.82%	+81.21%	54.55B
LONZA GROUP AG	-0.94%	+0.99%	+10.45%	+100.19%	53.59B
IQVIA HOLDINGS INC.	+2.76%	+0.87%	+27.92%	+55.07%	44.75B
BEONE MEDICINES AG	+2.00%	-3.39%	+17.83%	+119.04%	41.62B
REVOLUTION MEDICINES, INC.	+1.34%	-2.86%	+224.43%	+914.08%	39.91B
CELLTRION, INC.	+0.64%	-3.85%	+11.71%	+45.57%	32.47B
GENMAB A/S	+29.06%	+48.65%	+106.84%	+92.73%	26.7B
WUXI BIOLOGICS (CAYMAN) INC.	+3.72%	-7.45%	+24.25%	-2.99%	23.36B
Average	+4.24%	-1.36%	+44.74%	+137.93%	38.05B
Weighted average by Cap.	+3.23%	-0.50%	+47.53%	+161.45%